ArticleFrontiers in oncology2026
Expression of nectin-4 in squamous cell carcinoma of prostate: a pilot study and case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Squamous cell carcinoma of the prostate (SCCP) is a rare subtype of prostate cancer with a poor prognosis, and no consensus exists regarding the treatment of SCCP. Nectin-4, a cell adhesion molecule predominantly expressed in a wide variety of cancers, emerged as a promising therapeutic target due to its over expression. Case presentation: A 69-year-old male patient received transurethral resection of the prostate for lower urinary tract symptoms (LUTS) and was diagnosed with prostatic acinar adenocarcinoma. Androgen deprivation therapy (ADT) was administered, and 22 months later, the patient presented with LUTS again, and radical prostatectomy (RP) was performed; subsequent pathologic examination revealed mixed prostatic carcinoma, with the squamous and glandular components accounting for 70% and 30%, respectively. Immunohistochemical (IHC) staining of the mixed carcinoma tissue from the RP specimen demonstrated strong immunoreactivity for Nectin-4 exclusively in the squamous component, not the glandular component. A retrospective assay of seven additional SCCP specimens from our center showed the same result. In the current case, although apalutamide, a novel androgen receptor inhibitor, in combination with ADT and pelvic radiotherapy was administered 1 month postoperatively, the patient experienced both biochemical and radiographic progression. Conclusion: This is the first report of a case of hormonal therapy-induced SCCP, in which Nectin-4 was expressed exclusively in the squamous component, not the glandular component. Nectin-4 might be a therapeutic target for SCCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.